{"id":15707,"date":"2024-04-11T12:42:35","date_gmt":"2024-04-11T15:42:35","guid":{"rendered":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/"},"modified":"2024-04-11T12:42:35","modified_gmt":"2024-04-11T15:42:35","slug":"a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc","status":"publish","type":"post","link":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/","title":{"rendered":"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc."},"content":{"rendered":"<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA <b>ARTMS Inc.<\/b> (ARTMS) tem o prazer de anunciar que a aquisi\u00e7\u00e3o pela Telix Pharmaceuticals Limited (Telix) foi conclu\u00edda. Essa aquisi\u00e7\u00e3o aprimora ainda mais a integra\u00e7\u00e3o vertical da cadeia de suprimentos e da fabrica\u00e7\u00e3o da Telix, oferecendo um n\u00edvel maior de cadeia de suprimentos e controle regulat\u00f3rio sobre a produ\u00e7\u00e3o dos principais is\u00f3topos.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA ARTMS apoiar\u00e1 a produ\u00e7\u00e3o de alta efici\u00eancia, em larga escala e com boa rela\u00e7\u00e3o custo-benef\u00edcio de is\u00f3topos m\u00e9dicos comercialmente importantes para o portf\u00f3lio de produtos da Telix, como zirc\u00f4nio-89 (<sup>89<\/sup> Zr), g\u00e1lio-68 (<sup>68<\/sup> Ga), tecn\u00e9cio-99m (<sup>99m<\/sup> Tc) e cobre-64 (<sup>64<\/sup> Cu), e continuar\u00e1 fazendo parcerias com outras empresas radiofarmac\u00eauticas para garantir que esses is\u00f3topos essenciais estejam dispon\u00edveis sob demanda para os pacientes. Al\u00e9m disso, o portf\u00f3lio de tecnologias avan\u00e7adas de c\u00edclotrons da ARTMS tem aplica\u00e7\u00e3o imediata e diferencia\u00e7\u00e3o para a Telix na produ\u00e7\u00e3o de futuros is\u00f3topos terap\u00eauticos de emiss\u00e3o alfa comercialmente importantes, incluindo o act\u00ednio-225 (<sup>225<\/sup> Ac) e a astatina-211 (<sup>211<\/sup> At).<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA hist\u00f3ria da ARTMS est\u00e1 enraizada em um projeto financiado pelo governo canadense focado na produ\u00e7\u00e3o de alvos s\u00f3lidos de <sup>99m<\/sup> Tc. Ap\u00f3s a conclus\u00e3o bem-sucedida desse projeto, a inova\u00e7\u00e3o continuou e resultou em um conjunto completo de produtos PET. Em 2017, a ARTMS Inc. foi formada com o apoio e o financiamento inicial da Quark Venture, por meio de seu Global Health Sciences Fund (GHS) e das institui\u00e7\u00f5es fundadoras TRIUMF, BC Cancer, Lawson Health Research Institute e o Center for Probe Development. Em maio de 2020, a ARTMS concluiu uma capta\u00e7\u00e3o de recursos da S\u00e9rie A de US$ 20 milh\u00f5es que incluiu o GHS e deu as boas-vindas&agrave;Deerfield Management na fam\u00edlia ARTMS. Nos anos seguintes, a ARTMS desempenhou um papel fundamental na produ\u00e7\u00e3o alternativa de is\u00f3topos m\u00e9dicos, com foco na acelera\u00e7\u00e3o das capacidades de produ\u00e7\u00e3o dos c\u00edclotrons mais comumente instalados no mundo. A colabora\u00e7\u00e3o entre a equipe incompar\u00e1vel da ARTMS, seus investidores e membros fundadores resultou em uma organiza\u00e7\u00e3o verdadeiramente diferenciada.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Solomon Partners Securities LLC atuou como consultora financeira e a Norton Rose Fulbright Canada LLP atuou como consultora jur\u00eddica da ARTMS durante as negocia\u00e7\u00f5es e o processo de dilig\u00eancia relacionado&agrave;aquisi\u00e7\u00e3o pela Telix.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a ARTMS,<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nCom sede em Burnaby, British Columbia, Canad\u00e1, a ARTMS Inc. \u00e9 l\u00edder global no desenvolvimento de novas tecnologias e produtos que permitem a produ\u00e7\u00e3o de alta qualidade e alto rendimento dos is\u00f3topos de diagn\u00f3stico por imagem mais usados no mundo. O principal produto da ARTMS, o QUANTM Irradiation System (QIS<sup>TM<\/sup>), permite a produ\u00e7\u00e3o descentralizada, econ\u00f4mica e em larga escala de importantes is\u00f3topos m\u00e9dicos, como g\u00e1lio-68 (<sup>68<\/sup> Ga), zirc\u00f4nio-89 (<sup>89<\/sup> Zr), tecn\u00e9cio-99m (<sup>99m<\/sup> Tc) e cobre-64 (<sup>64<\/sup> Cu), usando ciclotrons m\u00e9dicos de distribuidores farmac\u00eauticos e hospitais, permitindo que os usu\u00e1rios controlem sua cadeia de suprimentos. A ARTMS comercializa essas premiadas e exclusivas inven\u00e7\u00f5es canadenses em \u00e2mbito global e tem a perspectiva de revolucionar o setor de medicina nuclear.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nPara obter mais informa\u00e7\u00f5es sobre o QUANTM Irradiation System\u2122 e a ARTMS, siga-nos no Twitter\/X @ARTMS_Inc\/X e no <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fca.linkedin.com%2Fcompany%2Fartms-products-inc&amp;esheet=53928566&amp;newsitemid=20240411996361&amp;lan=pt-BR&amp;anchor=LinkedIn&amp;index=1&amp;md5=237768d3a5d9b5ef605db4ee64b0333b\" rel=\"nofollow noopener\" shape=\"rect\" target=\"_blank\">LinkedIn<\/a> e visite <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.artms.ca%2F&amp;esheet=53928566&amp;newsitemid=20240411996361&amp;lan=pt-BR&amp;anchor=http%3A%2F%2Fwww.artms.ca%2F&amp;index=2&amp;md5=c89a0084c67f5c42ecc1e9d190e3c977\" rel=\"nofollow noopener\" shape=\"rect\" target=\"_blank\">http:\/\/www.artms.ca\/<\/a><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a Telix Pharmaceuticals Limited<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Telix \u00e9 uma empresa biofarmac\u00eautica focada no desenvolvimento e comercializa\u00e7\u00e3o de radiof\u00e1rmacos diagn\u00f3sticos e terap\u00eauticos, como tamb\u00e9m dispositivos m\u00e9dicos associados. A empresa tem sede em Melbourne, Austr\u00e1lia, com opera\u00e7\u00f5es internacionais nos Estados Unidos, Europa (B\u00e9lgica e Su\u00ed\u00e7a) e Jap\u00e3o. Telix est\u00e1 desenvolvendo um portf\u00f3lio de produtos em est\u00e1gios cl\u00ednicos e comerciais que visam atender a necessidades m\u00e9dicas significativas n\u00e3o atendidas em oncologia e doen\u00e7as raras. Telix est\u00e1 listada na Bolsa de Valores da Austr\u00e1lia (ASX: TLX).<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nVisite <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.telixpharma.com&amp;esheet=53928566&amp;newsitemid=20240411996361&amp;lan=pt-BR&amp;anchor=www.telixpharma.com&amp;index=3&amp;md5=e813fa55d0cb9826ce4f1fc4a1991571\" rel=\"nofollow noopener\" shape=\"rect\" target=\"_blank\">www.telixpharma.com<\/a> para obter mais informa\u00e7\u00f5es sobre a Telix, incluindo detalhes do pre\u00e7o das a\u00e7\u00f5es mais recente, an\u00fancios feitos para a ASX, apresenta\u00e7\u00f5es para investidores e analistas, comunicados de imprensa, detalhes de eventos e outras publica\u00e7\u00f5es que possam ser do seu interesse, voc\u00ea pode acessar o site da Telix e acompanhar a empresa no X e no LinkedIn.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO texto no idioma original deste an\u00fancio \u00e9 a vers\u00e3o oficial autorizada. As tradu\u00e7\u00f5es s\u00e3o fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que \u00e9 a \u00fanica vers\u00e3o do texto que tem efeito legal.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><span id=\"mmgallerylink-phrase\">Ver a vers\u00e3o original em businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20240411996361\/pt\/\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20240411996361\/pt\/<\/a><\/span><\/p>\n<p><b>Contato:<\/b><\/p>\n<p><b>Contato corporativo da ARTMS<br \/>\n<\/b><\/p>\n<p>Douglas Gentilcore\n<\/p>\n<p>ARTMS, Inc.\n<\/p>\n<p>Diretor-executivo\n<\/p>\n<p>E-mail: <a href=\"mailto:gentilcore@artms.ca\" rel=\"nofollow\" shape=\"rect\">gentilcore@artms.ca<br \/>\n<\/a><\/p>\n<\/p>\n<p><b>Contato comercial da ARTMS<br \/>\n<\/b><\/p>\n<p>Kevin Reimer\n<\/p>\n<p>ARTMS, Inc.\n<\/p>\n<p>Vice-presidente de Vendas e Marketing Globais\n<\/p>\n<p>E-mail: <a href=\"mailto:reimer@artms.ca\" rel=\"nofollow\" shape=\"rect\">reimer@artms.ca<br \/>\n<\/a><\/p>\n<\/p>\n<p>Rela\u00e7\u00f5es com investidores da Telix\n<\/p>\n<p>Sra. Kyahn Williamson\n<\/p>\n<p>Telix Pharmaceuticals Limited\n<\/p>\n<p>Vice-presidente s\u00eanior de Rela\u00e7\u00f5es com Investidores e Comunica\u00e7\u00f5es Corporativas\n<\/p>\n<p>E-mail: <a href=\"mailto:kyahn.williamson@telixpharma.com\" rel=\"nofollow\" shape=\"rect\">kyahn.williamson@telixpharma.com<\/a><\/p>\n<p><strong>Fonte: <\/strong><a href='http:\/\/www.businesswire.com\/portal\/site\/home\/' target='_blank' rel=\"noopener\">BUSINESS WIRE<\/a><img src='https:\/\/api.dino.com.br\/v2\/news\/tr\/303231?partnerId=3197' alt=\"\" style=\"border:0px;width:1px;height:1px;\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A ARTMS Inc. (ARTMS) tem o prazer de anunciar que a aquisi\u00e7\u00e3o pela Telix Pharmaceuticals Limited (Telix) foi conclu\u00edda. Essa aquisi\u00e7\u00e3o aprimora ainda mais a integra\u00e7\u00e3o vertical da cadeia de suprimentos e da fabrica\u00e7\u00e3o da Telix, oferecendo um n\u00edvel maior de cadeia de suprimentos e controle regulat\u00f3rio sobre a produ\u00e7\u00e3o dos principais is\u00f3topos. A ARTMS [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-15707","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc. - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc. - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"og:description\" content=\"A ARTMS Inc. (ARTMS) tem o prazer de anunciar que a aquisi\u00e7\u00e3o pela Telix Pharmaceuticals Limited (Telix) foi conclu\u00edda. Essa aquisi\u00e7\u00e3o aprimora ainda mais a integra\u00e7\u00e3o vertical da cadeia de suprimentos e da fabrica\u00e7\u00e3o da Telix, oferecendo um n\u00edvel maior de cadeia de suprimentos e controle regulat\u00f3rio sobre a produ\u00e7\u00e3o dos principais is\u00f3topos. A ARTMS [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-11T15:42:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp\" \/>\n<meta name=\"author\" content=\"DINO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"DINO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/\"},\"author\":{\"name\":\"DINO\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"headline\":\"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc.\",\"datePublished\":\"2024-04-11T15:42:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/\"},\"wordCount\":865,\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp\",\"articleSection\":[\"Not\u00edcias Corporativas\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/\",\"name\":\"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc. - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp\",\"datePublished\":\"2024-04-11T15:42:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\",\"name\":\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"description\":\"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\",\"name\":\"DINO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"caption\":\"DINO\"},\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/author\\\/dino\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc. - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/","og_locale":"pt_BR","og_type":"article","og_title":"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc. - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","og_description":"A ARTMS Inc. (ARTMS) tem o prazer de anunciar que a aquisi\u00e7\u00e3o pela Telix Pharmaceuticals Limited (Telix) foi conclu\u00edda. Essa aquisi\u00e7\u00e3o aprimora ainda mais a integra\u00e7\u00e3o vertical da cadeia de suprimentos e da fabrica\u00e7\u00e3o da Telix, oferecendo um n\u00edvel maior de cadeia de suprimentos e controle regulat\u00f3rio sobre a produ\u00e7\u00e3o dos principais is\u00f3topos. A ARTMS [&hellip;]","og_url":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/","og_site_name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","article_published_time":"2024-04-11T15:42:35+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp","type":"","width":"","height":""}],"author":"DINO","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"DINO","Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/#article","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/"},"author":{"name":"DINO","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"headline":"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc.","datePublished":"2024-04-11T15:42:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/"},"wordCount":865,"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp","articleSection":["Not\u00edcias Corporativas"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/","url":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/","name":"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc. - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/#primaryimage"},"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp","datePublished":"2024-04-11T15:42:35+00:00","author":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"breadcrumb":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20240411996361r1&amp;sid=brdno&amp;distro=ftp"},{"@type":"BreadcrumbList","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-telix-pharmaceuticals-limited-conclui-a-aquisicao-da-artms-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ocanal.com\/noticias\/corporativas\/"},{"@type":"ListItem","position":2,"name":"A Telix Pharmaceuticals Limited conclui a aquisi\u00e7\u00e3o da ARTMS, Inc."}]},{"@type":"WebSite","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website","url":"https:\/\/ocanal.com\/noticias\/corporativas\/","name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","description":"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ocanal.com\/noticias\/corporativas\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff","name":"DINO","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","caption":"DINO"},"url":"https:\/\/ocanal.com\/noticias\/corporativas\/author\/dino\/"}]}},"_links":{"self":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/15707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/comments?post=15707"}],"version-history":[{"count":0,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/15707\/revisions"}],"wp:attachment":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/media?parent=15707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/categories?post=15707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/tags?post=15707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}